+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Critical Care Therapeutics Market by Drug Class, Route of Administration, Patient Age Group, Indication, End-User - Global Forecast 2026-2032- Product Image
Critical Care Therapeutics Market by Drug Class, Route of Administration, Patient Age Group, Indication, End-User - Global Forecast 2026-2032- Product Image
Sale

Critical Care Therapeutics Market by Drug Class, Route of Administration, Patient Age Group, Indication, End-User - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4989766
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Critical Care Therapeutics Market is projected to reach USD 58.49 Billion in 2026. It is expected to continue growing at a CAGR of 5.54%, reaching USD 80.95 Billion by 2032.

The critical care therapeutics market is being shaped by rising ICU acuity, aging populations, antimicrobial resistance, and sustained demand for evidence-based treatment of sepsis, acute respiratory distress syndrome, shock, trauma, and post-surgical complications. Core ICU drug classes include anti-infectives, vasopressors, sedatives, analgesics, anticoagulants, corticosteroids, neuromuscular blockers, and supportive therapies used across emergency departments, intensive care units, and high-dependency care settings.

Demand is anchored in measurable disease burden. The World Health Organization identifies sepsis as a major global health threat, reporting that sepsis affects millions of people worldwide each year, while the CDC estimates that at least 1.7 million U.S. adults develop sepsis annually and nearly 350,000 adults who develop sepsis die during hospitalization or are discharged to hospice. These verified indicators reinforce the need for rapid-acting, protocol-driven, and outcome-focused critical care therapeutics that can support mortality reduction, shorter ICU stays, and improved hospital resource utilization.

Transformative Shifts in the Critical Care Landscape

The landscape is shifting from broad supportive care toward precision-guided, protocolized ICU therapy. Hospitals are increasingly standardizing sepsis bundles, antimicrobial stewardship programs, sedation-light strategies, thrombosis prevention, glycemic control, and renal- or hepatic-adjusted dosing to improve survival while controlling adverse events, drug resistance, and pharmacy costs.

Therapeutic development is also moving toward targeted inflammation control, pathogen-specific anti-infectives, rescue therapies for respiratory failure, and optimized hemodynamic support. At the same time, supply chain resilience has become a board-level priority after pandemic-era shortages exposed vulnerabilities in sedatives, vasopressors, antibiotics, anticoagulants, and injectable generics used in critical care. These shifts are intensifying demand for therapies supported by clinical guidelines, real-world evidence, and reliable manufacturing continuity.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding value across critical care therapeutics by improving early warning, patient stratification, dose optimization, and clinical trial design. AI-enabled sepsis detection, deterioration prediction, antimicrobial decision support, and therapeutic drug monitoring can help clinicians identify high-risk patients earlier, although these tools must be validated locally and monitored for bias, alert fatigue, explainability, and clinical safety.

For manufacturers and hospital systems, AI supports real-world evidence generation, pharmacovigilance signal detection, demand forecasting, and ICU inventory planning. The cumulative impact is a more data-driven therapeutic ecosystem where drug selection, stewardship, adverse-event tracking, and outcomes measurement are increasingly linked through electronic health records, pharmacy systems, laboratory data, and bedside monitoring platforms.

Key Regional Insights Across Critical Care Therapeutics

North America remains a high-value region for critical care therapeutics due to advanced ICU infrastructure, strong hospital pharmacy systems, high adoption of evidence-based sepsis protocols, and regulatory emphasis on drug safety, shortage mitigation, and antimicrobial stewardship. Europe benefits from universal health systems, structured procurement, and rigorous EMA-aligned safety expectations, while the European Union continues to prioritize health emergency preparedness, antimicrobial resistance response, clinical quality standards, and cross-border resilience in essential medicines.

Asia-Pacific is expanding as China, India, Japan, South Korea, Australia, and ASEAN countries invest in tertiary hospitals, emergency care capacity, specialty ICU services, and digital health infrastructure. Latin America shows growing demand led by Brazil and Mexico, although access variability, public-sector budget constraints, and uneven ICU distribution influence adoption. The Middle East, especially GCC markets, is strengthening critical care capacity through hospital modernization, specialty care investment, and medical tourism strategies. Africa presents long-term opportunity, but market development is closely tied to ICU bed availability, trained critical care workforce expansion, oxygen access, diagnostics, and reliable supplies of essential injectable medicines.

Key Group Insights for ICU Therapeutics Demand

ASEAN markets are benefiting from hospital expansion, medical tourism, and government-led efforts to strengthen emergency and intensive care capacity, particularly in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. GCC countries are prioritizing specialty care, digital hospitals, tertiary facilities, and high-acuity service lines, creating demand for premium ICU therapeutics, advanced anti-infectives, safe sedatives, anticoagulation protocols, and reliable hospital supply agreements.

The European Union emphasizes centralized regulatory quality, health technology assessment, pharmacovigilance, and antimicrobial stewardship, making evidence generation essential for access and adoption. BRICS economies combine large patient populations with expanding hospital infrastructure and rising critical care needs, but pricing pressure, reimbursement variation, and local manufacturing policies shape commercial strategy. G7 countries remain influential in clinical guidelines, regulatory science, health technology assessment, and advanced trial networks, while NATO-aligned health systems increasingly view critical care drug availability as part of emergency preparedness, civil resilience, and health security planning.

Key Country Insights for Critical Care Therapeutics

The United States leads in ICU drug utilization, innovation adoption, and real-world data generation, supported by large hospital networks, sophisticated pharmacy systems, and strong FDA oversight. Canada emphasizes quality-based procurement, antimicrobial stewardship, and equitable hospital access, while Mexico and Brazil represent important Latin American markets as public and private hospitals expand critical care capacity and improve access to essential injectable medicines.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain mature intensive care systems with strong stewardship requirements, pharmacovigilance expectations, and cost-effectiveness scrutiny. Russia continues to require localized access strategies due to procurement structures, regulatory requirements, and supply chain complexity. In Asia-Pacific, China and India offer scale-driven opportunity supported by expanding tertiary care, emergency medicine capacity, and domestic manufacturing, while Japan, South Korea, and Australia are defined by advanced clinical standards, high regulatory expectations, aging populations, and strong demand for safe, differentiated ICU medicines.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated ICU therapies that address sepsis, resistant infections, shock, acute respiratory failure, trauma, and high-risk post-operative complications. Commercial strategies should align with hospital protocols, pharmacy budget cycles, formulary evidence requirements, antimicrobial stewardship goals, and real-world outcomes rather than relying only on brand awareness.

Manufacturers should strengthen supply continuity for essential injectables, develop evidence packages that demonstrate mortality, length-of-stay, safety, resistance, and adverse-event benefits, and partner with health systems on AI-enabled monitoring, pharmacovigilance, antimicrobial optimization, and demand forecasting. Regional strategies should balance premium innovation in mature markets with affordability, local partnerships, regulatory readiness, and essential medicine access in emerging markets.

Research Methodology

This executive summary is developed through secondary research, regulatory review, epidemiological interpretation, and market intelligence synthesis. Sources considered include public health agencies, regulatory bodies, peer-reviewed clinical literature, hospital care guidelines, procurement trends, shortage notices, and verified information from organizations such as WHO, CDC, FDA, EMA, and national health authorities.

The methodology emphasizes triangulation across disease burden, ICU utilization, therapeutic class relevance, hospital purchasing behavior, regional access conditions, regulatory priorities, and technology adoption. Insights are structured to support strategic planning, competitive positioning, market entry assessment, and evidence-based SEO content for the critical care therapeutics market, while avoiding unsupported market sizing, share, estimation, or forecasting claims.

Conclusion

Critical care therapeutics is a resilient and clinically essential market supported by persistent ICU demand, sepsis burden, antimicrobial resistance, aging demographics, surgical complexity, trauma care needs, and hospital preparedness requirements. Growth in strategic relevance will be strongest where innovation, evidence, access, stewardship, and supply reliability converge.

The next phase of market leadership will favor organizations that combine clinically meaningful therapies with real-world evidence, AI-enabled decision support, robust pharmacovigilance, and region-specific access models. As intensive care becomes more data-driven, protocolized, and outcome-measured, therapeutics that improve survival, safety, antimicrobial effectiveness, and resource efficiency will define competitive advantage.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.1.1. Rising Critical Illness Burden Sustains Non-Discretionary ICU Drug Demand
4.3.1.2. AMR Converts Anti-Infectives Into a Strategic Critical Care Growth Engine
4.3.1.3. Ready-to-Administer Formats Monetize Safety, Speed, and Workforce Relief
4.3.1.4. Critical Medicine Policy Rewards Manufacturers That Prove Resilience
4.3.2. Key Restraints
4.3.2.1. Aggressive Institutional Pricing Pressure Limits Returns on Essential Generic ICU Drugs
4.3.2.2. Sterile Manufacturing Fragility Raises Cost and Limits Reliable Market Expansion
4.3.3. Key Opportunities
4.3.3.1. Commercialize Supply Reliability Through Assured-Access Critical Medicine Contracts
4.3.3.2. Build Premium Anti-Infective Platforms Around Resistant ICU Pathogens
4.3.3.3. Differentiate in Pediatric and Neonatal ICU Formulations Where Incumbent Focus Is Limited
4.3.4. Key Challenges
4.3.4.1. Rebuild the Essential-Medicine Business Case Before Price Compression Undermines Supply
4.3.4.2. Engineer Supply Chains for Tariffs, Sanctions, and Extreme Weather Rather Than Historical Averages
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Critical Care Therapeutics Market, by Drug Class
7.1. Cardiovascular Support Agents
7.1.1. Vasopressors
7.1.2. Inotropes
7.1.3. Hemodynamic Vasodilators
7.2. Analgesia, Sedation, & Paralysis Agents
7.2.1. Sedatives
7.2.2. Analgesics
7.2.3. Neuromuscular Blockers
7.2.4. Delirium Management Agents
7.3. Anti-Infective Agents
7.3.1. Antibacterials
7.3.2. Antifungals
7.3.3. Antivirals
7.4. Anti-Inflammatory & Immunomodulatory Agents
7.4.1. Corticosteroids
7.4.2. Targeted Immunomodulators
7.4.3. Plasma-Derived Immunotherapies
7.5. Coagulation & Hemostasis Agents
7.5.1. Anticoagulants
7.5.2. Antiplatelet Agents
7.5.3. Thrombolytics
7.5.4. Reversal & Hemostatic Agents
7.6. Metabolic & Renal Support Agents
7.6.1. Glycemic Control Agents
7.6.2. Fluid Balance Agents
7.6.3. Electrolyte & Acid-Base Agents
7.7. Gastrointestinal & Nutrition Support Agents
7.7.1. Stress Ulcer Prophylaxis Agents
7.7.2. Gastrointestinal Motility & Antiemetic Agents
7.7.3. Parenteral Nutrition Components
7.8. Respiratory Pharmacotherapy
7.8.1. Bronchodilators
7.8.2. Respiratory Support Pharmacotherapy
7.8.3. Respiratory Antivirals
8. Critical Care Therapeutics Market, by Route of Administration
8.1. Parenteral
8.1.1. Intravenous
8.1.2. Injection
8.1.2.1. Subcutaneous Injection
8.1.2.2. Intramuscular Injection
8.1.2.3. Intradermal Injection
8.1.2.4. Intraosseous Injection
8.2. Enteral and Mucosal
8.2.1. Oral
8.2.2. Enteral Tube
8.2.3. Mucosal
8.3. Inhalation
8.4. Topical and Local
9. Critical Care Therapeutics Market, by Patient Age Group
9.1. Neonates
9.2. Adults
9.3. Pediatrics
10. Critical Care Therapeutics Market, by Indication
10.1. Sepsis & Septic Shock
10.2. Hemodynamic Instability & Shock
10.3. Acute Respiratory Failure
10.4. Renal & Metabolic Critical Illness
10.5. Thrombosis & Bleeding Disorders
10.6. Pain, Agitation, Delirium, & Paralysis
10.7. Neurologic Critical Illness
11. Critical Care Therapeutics Market, by End-User
11.1. Ambulatory Surgical Centers
11.2. Home Healthcare
11.3. Hospitals
11.4. Long-Term Care Facilities
12. Asia-Pacific Critical Care Therapeutics Market
13. Europe Critical Care Therapeutics Market
14. North America Critical Care Therapeutics Market
15. Latin America Critical Care Therapeutics Market
16. Africa Critical Care Therapeutics Market
17. Middle East Critical Care Therapeutics Market
18. NATO Critical Care Therapeutics Market
19. G7 Critical Care Therapeutics Market
20. European Union Critical Care Therapeutics Market
21. BRICS Critical Care Therapeutics Market
22. ASEAN Critical Care Therapeutics Market
23. GCC Critical Care Therapeutics Market
24. United States Critical Care Therapeutics Market
25. China Critical Care Therapeutics Market
26. Germany Critical Care Therapeutics Market
27. Japan Critical Care Therapeutics Market
28. India Critical Care Therapeutics Market
29. United Kingdom Critical Care Therapeutics Market
30. France Critical Care Therapeutics Market
31. Canada Critical Care Therapeutics Market
32. Brazil Critical Care Therapeutics Market
33. Australia Critical Care Therapeutics Market
34. Italy Critical Care Therapeutics Market
35. Mexico Critical Care Therapeutics Market
36. South Korea Critical Care Therapeutics Market
37. Russia Critical Care Therapeutics Market
38. Spain Critical Care Therapeutics Market
39. Competitive Landscape
39.1. Market Concentration Analysis, 2025
39.1.1. Concentration Ratio (CR)
39.1.2. Herfindahl Hirschman Index (HHI)
39.2. Recent Developments & Impact Analysis, 2025
39.3. Product Portfolio Analysis, 2025
39.4. Benchmarking Analysis, 2025
40. Company Profiles
40.1. Pfizer Inc.
40.2. Fresenius Kabi AG
40.3. Baxter International Inc.
40.4. CSL Limited
40.5. B. Braun Melsungen SE
40.6. Merck & Co., Inc.
40.7. Sandoz Group AG
40.8. Grifols, S.A.
40.9. Teva Pharmaceutical Industries Limited
40.10. Hikma Pharmaceuticals PLC
40.11. Gilead Sciences, Inc.
40.12. Octapharma AG
40.13. Viatris Inc.
40.14. Aurobindo Pharma Limited
40.15. Aspen Pharmacare Holdings Limited
40.16. Dr. Reddy's Laboratories Limited
40.17. Sun Pharmaceutical Industries Limited
40.18. Amneal Pharmaceuticals, Inc.
40.19. Cipla Limited
40.20. Gland Pharma Limited
40.21. Intas Pharmaceuticals Limited
40.22. Sanofi S.A.
40.23. Piramal Pharma Limited
40.24. Astellas Pharma Inc.
40.25. Zydus Lifesciences Limited
40.26. Shionogi & Co., Ltd.
40.27. Amphastar Pharmaceuticals, Inc.
40.28. Basilea Pharmaceutica Ltd.
40.29. AstraZeneca PLC
40.30. Innoviva, Inc.
40.31. A. Menarini Industrie Farmaceutiche Riunite S.r.l.
40.32. AbbVie Inc.
40.33. Boehringer Ingelheim International GmbH
40.34. CorMedix Inc.
40.35. Eli Lilly and Company
40.36. GSK plc
40.37. Novo Nordisk A/S
40.38. Roche Holding Ltd
40.39. Spero Therapeutics, Inc.
40.40. Venatorx Pharmaceuticals, Inc.
List of Figures
FIGURE 1. GLOBAL CRITICAL CARE THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CRITICAL CARE THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL CRITICAL CARE THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL CRITICAL CARE THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL CRITICAL CARE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
FIGURE 23. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 37. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. EUROPEAN UNION CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. EUROPEAN UNION CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. BRICS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. BRICS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. ASEAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. ASEAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. GCC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. GCC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 49. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 50. GERMANY CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. UNITED KINGDOM CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. FRANCE CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. ITALY CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. RUSSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. SPAIN CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL CRITICAL CARE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CARDIOVASCULAR SUPPORT AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CARDIOVASCULAR SUPPORT AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CARDIOVASCULAR SUPPORT AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL VASOPRESSORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL VASOPRESSORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL VASOPRESSORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL INOTROPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL INOTROPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL INOTROPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL HEMODYNAMIC VASODILATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL HEMODYNAMIC VASODILATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL HEMODYNAMIC VASODILATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ANALGESIA, SEDATION, & PARALYSIS AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ANALGESIA, SEDATION, & PARALYSIS AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ANALGESIA, SEDATION, & PARALYSIS AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL SEDATIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL SEDATIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL SEDATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANALGESICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANALGESICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL NEUROMUSCULAR BLOCKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL NEUROMUSCULAR BLOCKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL NEUROMUSCULAR BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL DELIRIUM MANAGEMENT AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL DELIRIUM MANAGEMENT AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL DELIRIUM MANAGEMENT AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ANTI-INFECTIVE AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ANTI-INFECTIVE AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ANTI-INFECTIVE AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ANTIBACTERIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ANTIBACTERIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ANTIBACTERIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ANTIFUNGALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ANTIFUNGALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ANTIFUNGALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ANTIVIRALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ANTIVIRALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ANTI-INFLAMMATORY & IMMUNOMODULATORY AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ANTI-INFLAMMATORY & IMMUNOMODULATORY AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ANTI-INFLAMMATORY & IMMUNOMODULATORY AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL TARGETED IMMUNOMODULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL TARGETED IMMUNOMODULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL TARGETED IMMUNOMODULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL PLASMA-DERIVED IMMUNOTHERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL PLASMA-DERIVED IMMUNOTHERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL PLASMA-DERIVED IMMUNOTHERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL COAGULATION & HEMOSTASIS AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL COAGULATION & HEMOSTASIS AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL COAGULATION & HEMOSTASIS AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ANTICOAGULANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ANTICOAGULANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ANTIPLATELET AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ANTIPLATELET AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ANTIPLATELET AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL THROMBOLYTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL THROMBOLYTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL THROMBOLYTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL REVERSAL & HEMOSTATIC AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL REVERSAL & HEMOSTATIC AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL REVERSAL & HEMOSTATIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL METABOLIC & RENAL SUPPORT AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL METABOLIC & RENAL SUPPORT AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL METABOLIC & RENAL SUPPORT AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL GLYCEMIC CONTROL AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL GLYCEMIC CONTROL AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL GLYCEMIC CONTROL AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL FLUID BALANCE AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL FLUID BALANCE AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL FLUID BALANCE AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL ELECTROLYTE & ACID-BASE AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL ELECTROLYTE & ACID-BASE AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL ELECTROLYTE & ACID-BASE AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL GASTROINTESTINAL & NUTRITION SUPPORT AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL GASTROINTESTINAL & NUTRITION SUPPORT AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL GASTROINTESTINAL & NUTRITION SUPPORT AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL STRESS ULCER PROPHYLAXIS AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL STRESS ULCER PROPHYLAXIS AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL STRESS ULCER PROPHYLAXIS AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL GASTROINTESTINAL MOTILITY & ANTIEMETIC AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL GASTROINTESTINAL MOTILITY & ANTIEMETIC AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL GASTROINTESTINAL MOTILITY & ANTIEMETIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL PARENTERAL NUTRITION COMPONENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL PARENTERAL NUTRITION COMPONENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL PARENTERAL NUTRITION COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL RESPIRATORY PHARMACOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL RESPIRATORY PHARMACOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL RESPIRATORY PHARMACOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL BRONCHODILATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL BRONCHODILATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL RESPIRATORY SUPPORT PHARMACOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL RESPIRATORY SUPPORT PHARMACOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL RESPIRATORY SUPPORT PHARMACOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL RESPIRATORY ANTIVIRALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL RESPIRATORY ANTIVIRALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL RESPIRATORY ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL SUBCUTANEOUS INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL SUBCUTANEOUS INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL SUBCUTANEOUS INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL INTRAMUSCULAR INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL INTRAMUSCULAR INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL INTRAMUSCULAR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL INTRADERMAL INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL INTRADERMAL INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL INTRADERMAL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL INTRAOSSEOUS INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL INTRAOSSEOUS INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL INTRAOSSEOUS INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL ENTERAL AND MUCOSAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL ENTERAL AND MUCOSAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL ENTERAL AND MUCOSAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL ENTERAL TUBE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL ENTERAL TUBE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL ENTERAL TUBE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL MUCOSAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL MUCOSAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL MUCOSAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL INHALATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 147. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 148. GLOBAL TOPICAL AND LOCAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL TOPICAL AND LOCAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 150. GLOBAL TOPICAL AND LOCAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 151. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL NEONATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 153. GLOBAL NEONATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 154. GLOBAL NEONATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 155. GLOBAL ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 156. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 157. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 158. GLOBAL PEDIATRICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 159. GLOBAL PEDIATRICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 160. GLOBAL PEDIATRICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 161. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 162. GLOBAL SEPSIS & SEPTIC SHOCK MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 163. GLOBAL SEPSIS & SEPTIC SHOCK MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 164. GLOBAL SEPSIS & SEPTIC SHOCK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 165. GLOBAL HEMODYNAMIC INSTABILITY & SHOCK MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 166. GLOBAL HEMODYNAMIC INSTABILITY & SHOCK MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 167. GLOBAL HEMODYNAMIC INSTABILITY & SHOCK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 168. GLOBAL ACUTE RESPIRATORY FAILURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 169. GLOBAL ACUTE RESPIRATORY FAILURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 170. GLOBAL ACUTE RESPIRATORY FAILURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 171. GLOBAL RENAL & METABOLIC CRITICAL ILLNESS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 172. GLOBAL RENAL & METABOLIC CRITICAL ILLNESS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 173. GLOBAL RENAL & METABOLIC CRITICAL ILLNESS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 174. GLOBAL THROMBOSIS & BLEEDING DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 175. GLOBAL THROMBOSIS & BLEEDING DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 176. GLOBAL THROMBOSIS & BLEEDING DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 177. GLOBAL PAIN, AGITATION, DELIRIUM, & PARALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 178. GLOBAL PAIN, AGITATION, DELIRIUM, & PARALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 179. GLOBAL PAIN, AGITATION, DELIRIUM, & PARALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 180. GLOBAL NEUROLOGIC CRITICAL ILLNESS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 181. GLOBAL NEUROLOGIC CRITICAL ILLNESS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 182. GLOBAL NEUROLOGIC CRITICAL ILLNESS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 183. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 184. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 185. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 186. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 187. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 188. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 189. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 190. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 191. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 192. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. GLOBAL LONG-TERM CARE FACILITIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 194. GLOBAL LONG-TERM CARE FACILITIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 195. GLOBAL LONG-TERM CARE FACILITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 197. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 198. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 199. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESIA, SEDATION, & PARALYSIS AGENTS, 2018-2032 (USD MILLION)
TABLE 200. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTI-INFECTIVE AGENTS, 2018-2032 (USD MILLION)
TABLE 201. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY & IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 202. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COAGULATION & HEMOSTASIS AGENTS, 2018-2032 (USD MILLION)
TABLE 203. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY METABOLIC & RENAL SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 204. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL & NUTRITION SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 205. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 206. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 207. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 208. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
TABLE 209. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ENTERAL AND MUCOSAL, 2018-2032 (USD MILLION)
TABLE 210. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 211. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 212. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 213. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 214. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 215. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 216. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESIA, SEDATION, & PARALYSIS AGENTS, 2018-2032 (USD MILLION)
TABLE 217. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTI-INFECTIVE AGENTS, 2018-2032 (USD MILLION)
TABLE 218. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY & IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 219. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COAGULATION & HEMOSTASIS AGENTS, 2018-2032 (USD MILLION)
TABLE 220. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY METABOLIC & RENAL SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 221. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL & NUTRITION SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 222. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 223. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 224. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 225. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
TABLE 226. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ENTERAL AND MUCOSAL, 2018-2032 (USD MILLION)
TABLE 227. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 228. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 229. EUROPE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 230. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 231. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 232. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 233. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESIA, SEDATION, & PARALYSIS AGENTS, 2018-2032 (USD MILLION)
TABLE 234. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTI-INFECTIVE AGENTS, 2018-2032 (USD MILLION)
TABLE 235. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY & IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 236. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COAGULATION & HEMOSTASIS AGENTS, 2018-2032 (USD MILLION)
TABLE 237. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY METABOLIC & RENAL SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 238. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL & NUTRITION SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 239. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 240. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 241. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 242. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
TABLE 243. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ENTERAL AND MUCOSAL, 2018-2032 (USD MILLION)
TABLE 244. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 245. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 246. NORTH AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 247. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 248. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 249. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 250. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESIA, SEDATION, & PARALYSIS AGENTS, 2018-2032 (USD MILLION)
TABLE 251. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTI-INFECTIVE AGENTS, 2018-2032 (USD MILLION)
TABLE 252. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY & IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 253. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COAGULATION & HEMOSTASIS AGENTS, 2018-2032 (USD MILLION)
TABLE 254. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY METABOLIC & RENAL SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 255. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL & NUTRITION SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 256. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 257. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 258. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 259. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
TABLE 260. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ENTERAL AND MUCOSAL, 2018-2032 (USD MILLION)
TABLE 261. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 262. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 263. LATIN AMERICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 264. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 265. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 266. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 267. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESIA, SEDATION, & PARALYSIS AGENTS, 2018-2032 (USD MILLION)
TABLE 268. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTI-INFECTIVE AGENTS, 2018-2032 (USD MILLION)
TABLE 269. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY & IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 270. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COAGULATION & HEMOSTASIS AGENTS, 2018-2032 (USD MILLION)
TABLE 271. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY METABOLIC & RENAL SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 272. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL & NUTRITION SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 273. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 274. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 275. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 276. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
TABLE 277. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ENTERAL AND MUCOSAL, 2018-2032 (USD MILLION)
TABLE 278. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 279. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 280. AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 281. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 282. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 283. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 284. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESIA, SEDATION, & PARALYSIS AGENTS, 2018-2032 (USD MILLION)
TABLE 285. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTI-INFECTIVE AGENTS, 2018-2032 (USD MILLION)
TABLE 286. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY & IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 287. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COAGULATION & HEMOSTASIS AGENTS, 2018-2032 (USD MILLION)
TABLE 288. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY METABOLIC & RENAL SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 289. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL & NUTRITION SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 290. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 291. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 292. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 293. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
TABLE 294. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ENTERAL AND MUCOSAL, 2018-2032 (USD MILLION)
TABLE 295. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 296. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 297. MIDDLE EAST CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 298. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 299. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 300. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 301. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESIA, SEDATION, & PARALYSIS AGENTS, 2018-2032 (USD MILLION)
TABLE 302. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTI-INFECTIVE AGENTS, 2018-2032 (USD MILLION)
TABLE 303. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY & IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 304. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COAGULATION & HEMOSTASIS AGENTS, 2018-2032 (USD MILLION)
TABLE 305. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY METABOLIC & RENAL SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 306. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL & NUTRITION SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 307. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 308. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 309. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 310. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
TABLE 311. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ENTERAL AND MUCOSAL, 2018-2032 (USD MILLION)
TABLE 312. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 313. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 314. NATO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 315. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 316. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 317. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 318. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESIA, SEDATION, & PARALYSIS AGENTS, 2018-2032 (USD MILLION)
TABLE 319. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTI-INFECTIVE AGENTS, 2018-2032 (USD MILLION)
TABLE 320. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY & IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
TABLE 321. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COAGULATION & HEMOSTASIS AGENTS, 2018-2032 (USD MILLION)
TABLE 322. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY METABOLIC & RENAL SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 323. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL & NUTRITION SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 324. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
TABLE 325. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 326. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
TABLE 327. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
TABLE 328. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ENTERAL AND MUCOSAL, 2018-2032 (USD MILLION)
TABLE 329. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 330. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 331. G7 CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 332. EUROPEAN UNION CRITICAL CARE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 333. EUROPEAN UNION CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 334. EUROPEAN UNION CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR SUPPORT AGENTS, 2018-2032 (USD MILLION)
TABLE 335. EUROPEAN UNION CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESIA, SEDATION, &

Companies Mentioned

The companies featured in this Critical Care Therapeutics market report include:
  • Pfizer Inc.
  • Fresenius Kabi AG
  • Baxter International Inc.
  • CSL Limited
  • B. Braun Melsungen SE
  • Merck & Co., Inc.
  • Sandoz Group AG
  • Grifols, S.A.
  • Teva Pharmaceutical Industries Limited
  • Hikma Pharmaceuticals PLC
  • Gilead Sciences, Inc.
  • Octapharma AG
  • Viatris Inc.
  • Aurobindo Pharma Limited
  • Aspen Pharmacare Holdings Limited
  • Dr. Reddy's Laboratories Limited
  • Sun Pharmaceutical Industries Limited
  • Amneal Pharmaceuticals, Inc.
  • Cipla Limited
  • Gland Pharma Limited
  • Intas Pharmaceuticals Limited
  • Sanofi S.A.
  • Piramal Pharma Limited
  • Astellas Pharma Inc.
  • Zydus Lifesciences Limited
  • Shionogi & Co., Ltd.
  • Amphastar Pharmaceuticals, Inc.
  • Basilea Pharmaceutica Ltd.
  • AstraZeneca PLC
  • Innoviva, Inc.
  • A. Menarini Industrie Farmaceutiche Riunite S.r.l.
  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • CorMedix Inc.
  • Eli Lilly and Company
  • GSK plc
  • Novo Nordisk A/S
  • Roche Holding Ltd
  • Spero Therapeutics, Inc.
  • Venatorx Pharmaceuticals, Inc.

Table Information

Report AttributeDetails
No. of Pages196
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 58.49 Billion
Forecasted Market Value ( USD ) by 2032 $ 80.95 Billion
Compound Annual Growth Rate5.5%
Regions CoveredGlobal
No. of Companies Mentioned41

Related Topics

Related Reports

Critical Care Therapeutics - Global Strategic Business Report - Product Image

Critical Care Therapeutics - Global Strategic Business Report

  • Report
  • 280 Pages
  • Global
From
aIIbß3 Antagonists Market - Global Forecast 2026-2032 - Product Image

aIIbß3 Antagonists Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Acute Hyperammonemia Treatment Drugs Market - Global Forecast 2026-2032 - Product Image

Acute Hyperammonemia Treatment Drugs Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Pharmerging - Global Strategic Business Report - Product Image

Pharmerging - Global Strategic Business Report

  • Report
  • 198 Pages
  • Global
From
Australia Pharmaceutical Market Forecast Trends - Market Size, Share, Growth Analysis Report (2025-2034) - Product Image

Australia Pharmaceutical Market Forecast Trends - Market Size, Share, Growth Analysis Report (2025-2034)

  • Report
  • 107 Pages
  • Australia
From

About the Critical Care Therapeutics Market

The Critical Care Therapeutics market is a subset of the Pharmaceuticals industry, focusing on the development and distribution of drugs and treatments for life-threatening illnesses and conditions. These drugs and treatments are designed to improve the quality of life for patients with serious medical conditions, such as cancer, heart disease, and neurological disorders. The market is composed of a variety of companies, ranging from large pharmaceutical companies to smaller biotechnology firms. These companies are responsible for researching, developing, and manufacturing drugs and treatments for critical care. They also provide support services, such as clinical trials and regulatory compliance. Some of the major players in the Critical Care Therapeutics market include Pfizer, Merck, Novartis, Johnson & Johnson, and GlaxoSmithKline. Other companies in the market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and Sanofi. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.